News summary
[Huadong Medicinespinandcoinmaster: The subsidiary received the acceptance notice of the application for marketing authorization of Mivatinib tablets] Securities Times e Company News, Huadong Pharmaceutical (000963) announced on the evening of May 12 that its wholly-owned subsidiary Zhongmei Huadong received the "Acceptance Notice" issued by the State Food and Drug Administration.spinandcoinmaster...
Newsletter text
[Huadong Medicinespinandcoinmaster: The subsidiary received a notice of acceptance of the application for marketing authorization of Mihuatinib tablets] Securities Times e Company News, Huadong Pharmaceutical (000963) announced on the evening of May 12 that its wholly-owned subsidiary Zhongmei Huadong received the "Acceptance Notice" issued by the State Food and Drug Administration, Mihuatinib tablets (trade name: Mihuadong) submitted by Zhongmei Huadong as the applicant (trade name: Mihuadongspinandcoinmaster?）A marketing authorization application for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an L858R substitution mutation in exon 21 of the epidermal growth factor receptor (EGFR) was accepted.
